| Amount | Holding |
|---|---|
| 25.78% | Nasdaq Biotechnology Index Swap Ubs Ag |
| 22.82% | Ishares Biotech Swap Goldman Sachs International |
| 18.95% | Nasdaq Biotechnology Index Swap Bank Of America Na |
| 17.61% | Nasdaq Biotechnology Index Swap Societe Generale |
| 11.10% | Ishares Biotech Swap Bank Of America Na |
| 10.47% | Nasdaq Biotechnology Index Swap Citibank Na |
| 9.83% | Nasdaq Biotechnology Index Swap Goldman Sachs International |
| 7.35% | Nasdaq Biotechnology Index Swap Credit Suisse International |
| 5.32% | Vertex Pharmaceuticals Inc |
| 5.17% | Amgen Inc |
Expense Ratio Rating
7 /10
Expense Rating
1 /10
Market Score
8 /10
Category Score
0 /10
Market Size
8 /10
$BIB Alternatives
47%
FI Score
- bib
- ETF
- Alternative
- Leveraged Equities
ProShares Ultra Nasdaq Biotechnology
Expenses: 0.95% (Better than 1% of similar funds)
This is a bad choice for a Leveraged Equities Alternative fund. See why »